Inflation is causing pain for people across the country. As policymakers search for ways to help provide relief, some are erroneously tying inflation to prescription medicines. To make matters worse, this false premise is being used to build support for harmful policies.
Take for example the director of the National Economic Council, Brian Deese. After noting in a recent interview that “prices are unacceptably high,” Mr. Deese went on to call for government price controls to lower the cost of prescription drugs.
We also believe it’s important to make medicines affordable for patients, but let’s get a few facts straight.
Fact #1. Prescription drugs are NOT fueling inflation. Don’t take our word for it. The administration's own economic data show that’s the case. According to the Bureau of Labor Statistics, since May 2021, overall inflation surged by 8.6% while prices for medicines grew less than 2% even before accounting for discounts that insurers receive.
When these discounts are considered, the amount that health plans and others pay for medicines has grown even less. According to IQVIA, after factoring in billions of dollars in rebates and discounts, net prices for brand medicines increased on average just 1% last year and they’re expected to decline or stay flat over the next five years.
Fact #2: Abusive insurance practices drive up costs for patients. Even though medicines aren’t fueling inflation, there are still patients who struggle to afford their treatments. But their challenges largely stem from a broken insurance system that can lead patients to pay more for medicines than their insurance company.
Total rebates, discounts, and other payments from drug makers have more than tripled over the last decade and now exceed $200 billion. Yet health plans and pharmacy benefit managers (PBMs) often don’t share the savings they receive with patients at the pharmacy. Instead, patients with a deductible are forced to pay the full price of a medicine, while their health plan pockets the rebate.
Perhaps that helps explain why a recent survey found the top health care issue of voters is health insurance costs and coverage, with 58% who are concerned about their ability to afford their out-of-pocket health care costs and roughly 80% expressing support for requiring middlemen like insurance companies and PBMs to share the savings with patients.
Fact #3: Government price setting will NOT solve the real affordability challenges patients face. The current system isn’t fair for patients, but government price setting isn’t the answer. Instead, so-called Medicare “negotiation” would add a layer of government interference onto a system that too often benefits middlemen at patients’ expense. In short, government price setting would make a broken system worse, while at the same time jeopardizing future cures and treatments and risking patients’ access to life saving medicines. And here’s one final fact: there is a better way to help lower drug costs for patients, while preserving choice, access and future innovation.
Let’s stick to the facts and drive toward solutions that address the real challenges patients are experiencing.
Sarah Ryan
Sarah is a Senior Director of Public Affairs and spokesperson at PhRMA leading national earned media strategy and engagement for the organization and its executives. Prior to joining PhRMA, Sarah worked in public affairs at the U.S. Department of Justice. Outside of the office, Sarah can be found skiing in Breckenridge with her family and cheering on the N.C. State Wolfpack.
Sarah Sutton
Critics repeat same, misleading narrative on potential “costs” of new medicines
Insurance data: PBM reform has no material impact on premiums
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
3 Takeaways from POLITICO’s Health Care Summit
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
When it comes to the future of innovation, the ball is in policymakers’ court
AARP’s latest misleading report
New report: Hospitals mark up medicine prices 500%
read more
Key considerations as Congress works towards PAHPA reauthorization
Insulin: Key Facts on Access & Affordability
4 key facts on medicine prices and spending
Three facts about health care spending
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
Study finds hepatitis C cure saved Medicaid $15 billion
New data show how insurers and middlemen shift Rx costs onto patients
Busting 3 Myths About Copay Coupons
Making coupons count for patients at the pharmacy counter
By the Numbers: Patients lose when the government sets prices
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
Report finds PBMs are increasingly restricting patient access to medicines
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
Annual projections from NHE compared to actual health care spending
What’s really happening when it comes to prescription drug costs
Analysis: States can help patients save nearly $1,000 annually on their medicines
New analysis confirms hospitals markup prices for oncology therapies
How standardized plans can improve patients’ access to medicines
Correcting the record: Putting medicine costs and spending in context
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
Government price setting leaves behind families counting on new medicines
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
Research and development continues long after a medicine is initially approved
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
New study finds more than half of brand medicine spending goes to the supply chain and others
New NHE data show the true picture of health care spending
3 things to know about the importance of post-approval research and development
Guest post: Congress should not put future innovation at risk
What is missing in the current drug pricing plan
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
In the current health care debate, Congress has lost sight of what matters to U.S. voters
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
New poll shows Americans reject Medicare negotiation once they learn more about the policy
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
What is Kaiser Family Foundation up to?
Recognizing Hepatitis R&D on World Hepatitis Day
New reports shed light on key facts about medicines and affordability
How strengthening the biosimilar marketplace benefits patients
New report demonstrates development of new medicines relies on private sector expertise and investment
West Virginia becomes the first state to lower patient costs by sharing the savings
Top five issues voters want addressed in the administration’s first 100 days
Insurers shift medicine costs to patients with severe chronic illnesses
Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds
Survey found insurance premiums grew faster than inflation in 2020
Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually
Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas
Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs
Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report
New data show commercially insured patients face increasingly high cost sharing for brand medicines
Payers subject 80% of new RA and MS patients to utilization management restrictions
ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access
New rule makes it harder for patients to lower their out-of-pocket costs
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Fact Check: HCCI analysis overstates medicine spending and prices
Cancer medicines cost twice as much at hospitals, study finds
Nearly 50% of brand medicine spending goes to the supply chain and others
More evidence that medicine prices are growing at slowest rate in decades
Survey shows out-of-pocket costs top health care concern for voters
Four reasons why the radical Pelosi Plan is the wrong approach
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
Three things to know about the Part D GAO report
Setting the record straight on international reference pricing
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
Study finds hospitals continue to mark up medicines up to 500% of their cost
Three reasons why the latest Rx Savings Solutions analysis is misleading
"If Washington isn’t careful, we might leave innovation behind"
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
New study finds hospitals continue to push patients to costlier outpatient settings
4 Things to know about the IQVIA “Medicine Use and Spending” report
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
The PBM story you haven’t heard: Hidden fees quadrupled in two years
Health Affairs study misses the mark on medicine costs
New government data show medicine price growth continues to decline
Americans want to know more than just the list price of a medicine—and we’re answering their call
What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
New study finds some hospitals mark up medicine prices at least 700 percent
69 percent of patients abandon medicines when cost sharing is more than $250
New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs
Medicare Part D cliff ahead
Part D cliff looms for seniors, as program stability could be in jeopardy
Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually
New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
Event tomorrow: Making the biopharmaceutical supply chain work for patients
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
Advance price notification: A transparency measure that fails patients
New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed
Video: How does the supply chain shape brand-name medicine prices?
4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report
ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth
Copay coupons can help ease patients’ out-of-pocket costs
Oregon’s HB 4005 fails to deliver savings for patients
PhRMA launches new consumer-facing Let’s Talk About Cost website
NHE Data: Medicine spending grew just 1.3 percent in 2016
Video: What is a results-based contract?
Excerpts from testimony by PhRMA’s Lori Reilly
4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box
New PhRMA resources chock full of biopharma industry facts
New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs
New data put medicine costs and spending in context
In the OECD other health care services will be ten times prescription medicine spending growth over next decade
Medicines have significantly increased chances of cancer survival around the globe
Why won’t the insurance industry tell the truth about medicine costs?
4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
How innovative medicines are benefiting countries across the globe
ICYMI: 3 new reports show dramatic slowdown in medicine spending growth
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Prescription drug prices are not fueling inflation
Drug Cost
Prescription drug prices are not fueling inflation
Prescription drug prices are not fueling inflation